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Lipid disequilibrium disrupts ER proteostasis 
by impairing ERAD substrate glycan trimming 
and dislocation
ABSTRACT The endoplasmic reticulum (ER) mediates the folding, maturation, and deploy-
ment of the secretory proteome. Proteins that fail to achieve their native conformation are 
retained in the ER and targeted for clearance by ER-associated degradation (ERAD), a sophis-
ticated process that mediates the ubiquitin-dependent delivery of substrates to the 26S 
proteasome for proteolysis. Recent findings indicate that inhibition of long-chain acyl-CoA 
synthetases with triacsin C, a fatty acid analogue, impairs lipid droplet (LD) biogenesis and 
ERAD, suggesting a role for LDs in ERAD. However, whether LDs are involved in the ERAD 
process remains an outstanding question. Using chemical and genetic approaches to disrupt 
diacylglycerol acyltransferase (DGAT)–dependent LD biogenesis, we provide evidence that 
LDs are dispensable for ERAD in mammalian cells. Instead, our results suggest that triacsin C 
causes global alterations in the cellular lipid landscape that disrupt ER proteostasis by inter-
fering with the glycan trimming and dislocation steps of ERAD. Prolonged triacsin C treat-
ment activates both the IRE1 and PERK branches of the unfolded protein response and ulti-
mately leads to IRE1-dependent cell death. These findings identify an intimate relationship 
between fatty acid metabolism and ER proteostasis that influences cell viability.
INTRODUCTION
As the entry point into the secretory pathway, the endoplasmic re-
ticulum (ER) is host to an extensive cohort of enzymes and chaper-
ones that coordinate the folding, modification, and deployment of 
a large fraction of the proteome. Failure of secretory proteins to 
achieve their native structure due to mutations, errors in transcrip-
tion or translation, protein damage, or inefficient folding can have 
dire consequences for cellular physiology and has been implicated 
in the etiology of numerous human diseases (Guerriero and Brodsky, 
2012). Incorrect protein folding not only can result in a reduction in 
protein activity (i.e., loss of function), but it can also lead to the gen-
eration of cytotoxic protein aggregates (i.e., gain of function). To 
ensure the fidelity of the secretory proteome, the ER has evolved a 
quality control system that detects terminally misfolded and un-
oligomerized proteins and targets them for clearance via a process 
known as ER-associated degradation (ERAD; Olzmann et al., 2013a; 
Christianson and Ye, 2014; Stevenson et al., 2016). The cell also re-
sponds to perturbations in ER homeostasis by activating the un-
folded protein response (UPR; Walter and Ron, 2011; Wang and 
Kaufman, 2016), a set of signaling pathways that enhance the over-
all folding capacity of the ER.
ERAD involves a series of spatially and temporally coupled steps 
that mediate substrate recognition, dislocation (also known as ret-
rotranslocation) across the ER membrane into the cytoplasm, ubiq-
uitination, and targeting to the proteasome for proteolysis (Olzmann 
et al., 2013a; Christianson and Ye, 2014; Stevenson et al., 2016). 
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(Garbarino et al., 2009; Petschnigg et al., 2009; Olzmann and 
Kopito, 2011; Velázquez et al., 2016).
Indirect experimental evidence supporting a functional role for 
LDs in ERAD came from studies employing triacsin C, a polyunsatu-
rated fatty acid analogue that inhibits long-chain acyl-CoA synthe-
tases (ACSLs; Tomoda et al., 1987; Igal et al., 1997) and blocks LD 
biogenesis (Fujimoto et al., 2007; Kassan et al., 2013). These stud-
ies found that triacsin C impaired the degradation kinetics of sev-
eral ERAD substrates, including the null Hong Kong (NHK) mutant 
of α-1 antitrypsin (Klemm et al., 2011), a truncated variant of ri-
bophorin I (Klemm et al., 2011), class I MHC heavy chain (Klemm 
et al., 2011), and HMGCR (Hartman et al., 2010; Jo et al., 2013). 
Together these findings led to multiple models of how LDs might 
be involved in ERAD (Ploegh, 2007; Hartman et al., 2010; Klemm 
et al., 2011; Suzuki et al., 2012; Jo et al., 2013; Vevea et al., 2015): 
1) LD biogenesis is coupled to the dislocation of luminal ERAD sub-
strates via the formation of transient pores in the membrane or the 
dislocation of integral membrane ERAD substrates via capture in 
the membrane of an exiting LD, 2) ERAD substrate dislocation and 
ubiquitination preferentially occur in LD-associated ER subdo-
mains, and/or 3) ERAD substrates are sequestered on the surface of 
LDs as an intermediate step en route to the proteasome. Although 
these models are attractive, triacsin C is not a specific inhibitor of 
LD biogenesis, as it also affects unrelated processes that require 
activated fatty acids (e.g., de novo phospholipid synthesis; Igal 
et al., 1997). Moreover, the degradation kinetics of several ERAD 
substrates was unaffected in a strain of yeast lacking LDs (Olzmann 
and Kopito, 2011; Nakatsukasa and Kamura, 2016), indicating ei-
ther that LD formation is not essential for ERAD or that there are 
unrecognized differences between the ERAD process in yeast and 
mammalian cells. Thus, the functional relationship between ERAD 
and LDs remains unresolved.
In this study, we focused our attention on the effect of triacsin C 
on ERAD and the potential requirement of LDs for ERAD in mam-
malian cells. Our results demonstrate that, as in yeast (Olzmann and 
Kopito, 2011; Nakatsukasa and Kamura, 2016), LDs are dispensable 
for ERAD in mammalian cells. However, our data indicate that triac-
sin C causes widespread changes in the cellular lipid composition, 
impairs ERAD substrate glycan trimming and dislocation, and in-
duces the UPR, culminating in cell death. These findings support a 
fundamental connection between fatty acid metabolism and ER 
proteostasis.
RESULTS
Inhibition of long-chain acyl-CoA synthetases with triacsin C 
impairs select ERAD pathways
To examine the effect of triacsin C on ERAD, we analyzed the deg-
radation kinetics of a panel of substrates that reflect a range of to-
pologies and use distinct degradation pathways (Figure 1A). The 
panel included an endogenous ERAD substrate, CD147, which is a 
glycosylated type I transmembrane protein that is recognized as an 
unassembled subunit of an oligomeric complex and is constitutively 
degraded by a Hrd1/SEL1L pathway (Tyler et al., 2012). We also 
tested two exogenously expressed mutant substrates: the NHK mu-
tant of α-1 antitrypsin—a soluble, luminal substrate degraded by a 
Hrd1/SEL1L pathway (Christianson et al., 2008; Hosokawa et al., 
2008)—and the ∆F508 mutant cystic fibrosis transmembrane con-
ductance regulator (CFTR∆F508)—a polytopic integral membrane 
substrate degraded by multiple E3 ligase pathways (Meacham 
et al., 2001; Younger et al., 2006; Morito et al., 2008).
To determine the kinetics of triacsin C treatment on ERAD dis-
ruption, we performed a time course of triacsin C incubation and 
Although the mechanism by which substrates are triaged for degra-
dation is incompletely understood, it is clear that the structure of 
substrate-conjugated N-linked glycans provides a “molecular code” 
that plays a determining role in the fate of secretory proteins (Xu 
and Ng, 2015). During insertion into the ER, the majority of the se-
cretory proteome is modified by covalent attachment of a trianten-
nary glycan moiety (Cherepanova et al., 2016). Progressive trimming 
by ER-resident mannosidases exposes an α-1,6–linked mannose, 
which acts as a signal for ERAD and is recognized by the mannose 
6-phosphate receptor homology (MRH) domain of the ER lectin, 
OS-9, and possibly a second ER lectin, XTP3-B (Satoh et al., 2010). 
These two ER lectins interact with the Hrd1 luminal adaptor SEL1L 
(Christianson et al., 2008; Mueller et al., 2008; Tyler et al., 2012), 
facilitating substrate delivery for dislocation. Most models posit that 
the AAA ATPase VCP (also known as p97) then extracts substrates 
from proteinaceous pores in the membrane, possibly formed by the 
E3 ubiquitin ligase Hrd1 (Carvalho et al., 2010; Stein et al., 2014; 
Baldridge and Rapoport, 2016), the derlin family of proteins (Lilley 
and Ploegh, 2004; Ye et al., 2004; Greenblatt et al., 2011; Mehnert 
et al., 2014), or, in some cases, the Sec 61 translocon (Plemper et al., 
1997; Scott and Schekman, 2008).
In addition to its role as a protein-folding compartment, the ER 
functions as a major site of lipid metabolism, mediating the synthe-
sis of important lipids (e.g., phospholipids, sterols, and neutral lip-
ids) and the biogenesis of lipid storage organelles called lipid drop-
lets (LDs; Walther and Farese, 2012; Pol et al., 2014; Hashemi and 
Goodman, 2015). LDs are ubiquitous, conserved organelles com-
posed of a neutral lipid core (e.g., triacylglycerol [TAG] and sterol 
esters) encircled by a phospholipid monolayer. Whereas the hydro-
phobic core of LDs is devoid of proteins, the bounding phospho-
lipid monolayer is decorated with a unique proteome that regulates 
LD growth, breakdown, and trafficking. LDs function as dynamic 
repositories of lipids, protecting the cell from fatty acid–induced 
toxicity (Listenberger et al., 2003) and providing the cell with an “on-
demand” source of lipids for membrane biogenesis (Kurat et al., 
2009), energy production via β-oxidation (Rambold et al., 2015), and 
use as ligands in lipid signaling pathways (Haemmerle et al., 2011; 
Tang et al., 2013). Several unexpected roles have also been identi-
fied for LDs, such as the regulation of the hepatitis C life cycle 
(Miyanari et al., 2007; Herker et al., 2010), the sequestration of his-
tones (Cermelli et al., 2006; Anand et al., 2012), and the control of 
cytosolic inclusion body clearance (Moldavski et al., 2015).
Reports have identified a number of intriguing links between 
ERAD and LDs. A subset of proteins implicated in ERAD, including 
UBXD8, UBXD2, VCP, AUP1, and Ube2g2, were identified in pro-
teomic analyses of buoyant, LD-enriched biochemical fractions 
(Brasaemle et al., 2004; Liu et al., 2004; Hodges and Wu, 2010), 
and the localization of these proteins to the LD surface was con-
firmed by fluorescence microscopy (Mueller et al., 2008; Zehmer 
et al., 2009; Klemm et al., 2011; Spandl et al., 2011; Suzuki et al., 
2012; Jo et al., 2013; Olzmann et al., 2013b). This subset of ERAD 
factors has been implicated in the regulation of LD abundance, 
size, and clustering (Mueller et al., 2008; Zehmer et al., 2009; 
Klemm et al., 2011; Spandl et al., 2011; Suzuki et al., 2012; Jo 
et al., 2013; Olzmann et al., 2013b), but whether these effects on 
LDs are related to their functions in ERAD remains to be deter-
mined. ERAD substrates have also been observed on the LD sur-
face (e.g., ApoB100 [Ohsaki et al., 2006; Suzuki et al., 2012]) and 
in ER subdomains that are closely juxtaposed to LDs (e.g., 3-hyd-
roxy-3-methylglutaryl-coenzyme A reductase [HMGCR; Hartman 
et al., 2010]). In addition, ER stress induces LD biogenesis (Fei 
et al., 2009; Vevea et al., 2015), and loss of LDs activates the UPR 
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analyzed the degradation of CD147 during 
emetine translation shutoff (Figure 1, B–D). 
As expected (Tang, 2004; Tyler et al., 
2012), CD147 migrated as two primary 
species: a high–molecular weight plasma 
membrane form bearing complex glycans 
(CD147(mature [Mat.])) and a lower–mole-
cular weight ER form bearing the core-
glycan structure (CD147(CG); Figure 1C). 
CD147(CG) was degraded during the 6-h 
emetine chase (Figure 1, C and D). Addition 
of triacsin C at time 0 of the emetine chase 
had no effect on CD147(CG) degradation 
(Figure 1, C and D). Increasing stabilization 
of CD147(CG) was observed as the triacsin 
C preincubation time was lengthened, with 
a maximal stabilization occurring after a 
16-h triacsin C pretreatment (Figure 1, C 
and D). Using the 16-h triacsin C pretreat-
ment, we analyzed the degradation kinetics 
of our full panel of ERAD substrates (Figure 
1, E–J). The Hrd1 substrate CD147(CG) was 
stabilized by triacsin C pretreatment (Figure 
1, E and F). Although the majority of newly 
synthesized CD147 is degraded by ERAD, a 
small fraction can correctly assemble and 
mature by trafficking through the Golgi to 
the plasma membrane (Tang, 2004; Tyler 
et al., 2012). To account for both fates of 
CD147, we performed radioactive pulse-
chase experiments (Supplemental Figure 
S1A). Over the 6-h time course of our ex-
periment, no CD147 maturation was de-
tected, and triacsin C pretreatment stabi-
lized CD147(CG). These results indicate that 
the effect of triacsin C is due to impairment 
of CD147 degradation rather than matura-
tion. The Hrd1 luminal substrate NHK–
green fluorescent protein (GFP) was also 
stabilized by triacsin C pretreatment (Figure 
1, G and H). No secretion of NHK-GFP was 
observed in this cell line (Supplemental 
Figure S1B). In contrast to CD147 and NHK-
GFP, CFTR∆F508 degradation kinetics was 
unaffected by the triacsin C pretreatment 
(Figure 1, I and J). These data demonstrate 
that treatment with the ACSL inhibitor triac-
sin C impairs select ERAD pathways.
FIGURE 1: Triacsin C inhibits a subset of ERAD pathways. (A) ERAD substrate panel, indicating 
substrate topology and degradation pathway(s). Substrates are indicated in blue and ERAD 
components in green. Yellow triangles indicate N-linked glycans. (B) Triacsin C treatment time 
course. Triacsin C was added for the indicated times (blue bars) and maintained in the medium 
throughout the emetine chase. (C) HEK293 cells were pretreated with 1 µg/ml triacsin C for the 
indicated times (as depicted in B), followed by addition of 75 µM emetine for 6 h. CD147 levels 
were assessed by immunoblotting of SDS lysates. (D) The relative CD147(CG) levels in C were 
quantified and are presented as percentage of the levels at time 0 h (n = 3). Asterisk indicates 
significant stabilization (p < 0.05). (E) HEK293 cells were pretreated with vehicle or 1 µg/ml 
triacsin C for 16 h, followed by 75 µM emetine for the indicated times. CD147 levels were 
assessed by immunoblotting of SDS lysates. (F) The relative levels of CD147(CG) in E were 
quantified and are presented as percentage of the levels at time 0 h (n = 3). (G) HEK293 cells 
expressing NHK-GFP were pretreated with vehicle or 1 µg/ml triacsin C for 16 h, followed by 
75 µM emetine for the indicated times. NHK-GFP levels were assessed by immunoblotting of 
SDS lysates. (H) The relative levels of NHK-GFP in G were quantified and are presented as 
percentage of the levels at time 0 h (n = 3). 
(I) HEK293 cells expressing CFTR∆F508 were 
pretreated with vehicle or 1 µg/ml triacsin C 
for 16 h, followed by 75 µM emetine for the 
indicated times. CFTR∆F508 levels were 
assessed by immunoblotting of SDS lysates. 
(J) The relative levels of CFTR∆F508 in I were 
quantified and are presented as percentage 
of the levels at time 0 h (n = 4). Mat., mature; 
CG, core glycosylated. Error bars indicate 
SEM.
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ally affect the degradation of cytosolic UPS 
substrates.
After dislocation, ERAD substrates are 
deglycosylated by the cytosolic peptide:N-
glycanase (PNGase) and cleared by the 
UPS (Olzmann et al., 2013a; Xu and Ng, 
2015). Thus, the presence and accu-
mulation of a deglycosylated form of ERAD 
substrates reflect inefficient coupling of 
dislocation with proteasomal degradation. 
Incubation with the proteasome inhibitor 
MG-132 during an emetine chase resulted 
in the accumulation of deglycosylated 
CD147 (CD147(-CHO)), indicating the 
buildup of cytosolically dislocated CD147 
(Figure 2C). CD147 deglycosylated in vitro 
by incubation with the glycosidase PNGase 
F resolved at the same molecular weight as 
the CD147 band that accumulated in MG-
132–treated cells, and no additional lower–
molecular weight forms appeared (Supple-
mental Figure S2), confirming the identify 
of the CD147(-CHO) species. A portion of 
CD147 also migrated in a high–molecular 
weight smear, likely representing ubiquiti-
nated CD147 (Figure 2C). In contrast to 
MG-132, triacsin C pretreatment solely sta-
bilized CD147(CG); deglycosylated CD147 
and ubiquitinated CD147 were absent 
(Figure 2C). Together, these data indicate 
that triacsin C impairs ERAD upstream of 
the proteasome and does not cause a 
global defect in the UPS.
Triacsin C does not impair protein 
secretion
Dysregulated lipid metabolism can alter or-
ganelle morphology and function (Han 
et al., 2008; Adeyo et al., 2011; Thibault 
et al., 2012), and disruptions in ER-to-Golgi 
trafficking reduce the degradation of some 
ERAD substrates (Caldwell et al., 2001; 
Vashist et al., 2001; Taxis et al., 2002). To ex-
amine the function of the secretory pathway, 
we analyzed the secretion of hemagglutinin-
tagged transthyretin (TTR-HA), a tetrameric protein that is normally 
secreted into the serum, where it functions as a carrier of the thyroid 
hormone thyroxine. Similar levels of TTR-HA were immunoprecipi-
tated from media isolated from cells incubated in the presence or 
absence of triacsin C (Figure 2, D and E), indicating that triacsin C 
pretreatment does not affect TTR secretion. Furthermore, the over-
all morphology of the ER (Figure 2F) and Golgi complex (Figure 2G) 
remained unperturbed by a triacsin C pretreatment at the resolution 
of fluorescence deconvolution microscopy. Together, these results 
indicate that the secretory system remains functionally and morpho-
logically intact after a 16-h triacsin C treatment.
Triacsin C impairs CD147 glycan trimming
Our initial results indicated that triacsin C affects ERAD upstream 
of the proteasome (Figure 2). To determine more precisely the 
steps in ERAD that are compromised, we focused our attention on 
the degradation of the endogenous substrate CD147, which was 
Triacsin C does not generally inhibit the 
ubiquitin-proteasome system
Our finding that triacsin C inhibits the degradation of a subset of 
ERAD substrates suggests that triacsin C treatment does not gen-
erally inhibit the ubiquitin-proteasome system (UPS). In agree-
ment with this notion, ubiquitinated proteins accumulated in cells 
treated with the proteasome inhibitor MG-132, but not with triac-
sin C (Figure 2A). To assess more directly the effect of triacsin C on 
the degradation of cytosolic proteins, we used flow cytometry to 
measure the degradation kinetics of a cytosolic UPS reporter 
(Figure 2B). This reporter consists of the Venus fluorescent protein 
fused to a destabilized domain (Venus-DD), a variant FK506-bind-
ing domain from FKBP12 that, in the absence of the small mole-
cule shield-1, is misfolded and rapidly degraded via the UPS 
(Banaszynski et al., 2006; Egeler et al., 2011; Bersuker et al., 2016). 
Triacsin C had no significant effect on the constitutive degradation 
of Venus-DD (Figure 2B), indicating that triacsin C does not gener-
FIGURE 2: Triacsin C does not generally inhibit the ubiquitin-proteasome system or protein 
secretion. (A) SDS lysates from HEK293 cells incubated with 1 µg/ml triacsin C for 16 h or 10 µM 
MG-132 for 6 h were analyzed by immunoblotting. (B) U2OS cells stably expressing Venus-DD 
were incubated with vehicle or 1 µg/ml triacsin C for 16 h, followed by emetine treatments for 
the indicated times. Venus fluorescence levels were monitored by flow cytometry and quantified 
as the percentage of the levels at time 0 h (n = 3). (C) HEK293 cells were incubated with vehicle 
or 1 µg/ml triacsin C for 16 h and then treated with 75 µM emetine for the indicated times. 
Where indicated, 10 µM MG-132 was added at the beginning of the emetine chase. The levels 
of the different forms of CD147 were assessed by immunoblotting of SDS lysates. (D) HEK293 
cells expressing TTR-HA were treated with vehicle or 1 µg/ml triacsin C for 16 h. Cells were 
washed with PBS, and the medium was replaced with serum-free OPTI-MEM containing vehicle 
or 1 µg/ml triacsin C for the remaining 6 h. Lysates and TTR-HA immunoprecipitated from the 
media were analyzed by immunoblotting. (E) The levels of TTR-HA in the media were quantified 
from D and are presented as percentage of the levels in the control sample (n = 3). (F, G) The 
morphology of the ER, anti-KDEL (green) and the Golgi complex, anti-GM130 (green), in HeLa 
cells treated with vehicle or 1 µg/ml triacsin C for 16 h was analyzed by immunofluorescence 
microscopy. Nuclei were stained with DAPI (blue). Scale bar, 10 µm. Mat., mature; CG, core 
glycosylated; -CHO, deglycosylated. Error bars indicate SEM.
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trimming, we separated CD147 on large-
format SDS–PAGE gels (Figure 3A). On 
these larger gels, the variety of CD147 gly-
coforms becomes evident, and CD147(CG) 
is resolved as approximately five bands 
(Figure 3A). Treatment of lysates in vitro 
with PNGase F collapsed all CD147 forms 
into a single band of ∼29 kDa (Figure 3D), 
consistent with the conjecture that the vari-
ations in the CD147 banding pattern re-
flect the diversity of CD147 glycoforms.
During the course of an emetine trans-
lation shutoff experiment, the upper 
CD147(CG) bands were rapidly lost (Figure 
3, A and B, vehicle), whereas the lower 
bands displayed a slight lag period before 
clearance (Figure 3, A and C, vehicle). 
These results are consistent with the con-
version of CD147(CG) from a slower-mi-
grating, untrimmed form into a faster-mi-
grating, trimmed form before degradation. 
Treatment with the mannosidase inhibitor 
kifunensine (Figure 3, A–C, kifunensine) 
or the glucosidase inhibitor deoxynojirimy-
cin (Supplemental Figure S3) stabilized 
CD147(CG) in the slower-migrating form, 
providing evidence that these bands repre-
sent an untrimmed form of CD147(CG). It is 
worth noting that CD147(CG) continued to 
be degraded in the presence of kifunen-
sine (Figure 3A, kifunensine), albeit at a 
slower rate, indicating either that glycan 
trimming is not a strict requirement for 
CD147(CG) degradation or that kifunen-
sine inhibition of glycan trimming is incom-
plete. Cotreatment with kifuensine and de-
oxynojirimycin did not result in additional 
stabilization (Supplemental Figure S3). 
Analysis of CD147(CG) in cells pretreated 
with triacsin C revealed a significantly re-
duced rate of CD147(CG) conversion from 
untrimmed to the trimmed glycoform 
(Figure 3, A–C, triacsin C), similar to the ef-
fect of kifunensine. In contrast, blocking 
CD147(CG) degradation at a downstream 
step with the VCP inhibitor CB-5083 re-
sulted in the accumulation of a lower–
molecular weight, presumably highly 
trimmed form of CD147(CG) (Figure 3, 
A–C, CB-5083). These data suggest that 
triacsin C impairment in ERAD is caused, at 
least in part, through inhibition of substrate 
glycan trimming.
Triacsin C disrupts CD147 delivery to the Hrd1 dislocation 
complex
CD147 is degraded via an ERAD pathway that requires Hrd1, SEL1L, 
and, to some extent, the lectins OS-9 and XTP3-B (Tyler et al., 2012). 
The Hrd1 dislocation complex is a membrane-embedded, macro-
molecular complex (Mueller et al., 2008; Christianson et al., 2012). 
Several properties of membrane lipids can influence the interac-
tions and functions of membrane-embedded protein complexes 
strongly stabilized by triacsin C (Figure 1). Glycan trimming is often 
believed to be one of the most upstream events in ERAD, poten-
tially acting as a timing mechanism that releases a substrate from 
futile calnexin/calreticulin folding cycles and facilitates targeting 
for degradation by enabling direct interactions with the ERAD-im-
plicated lectins (Xu and Ng, 2015). The various trimmed CD147(CG) 
glycoforms are not resolved on small SDS–PAGE gels. Therefore, 
to examine a potential effect of triacsin C on CD147(CG) glycan 
FIGURE 3: Triacsin C impairs ERAD substrate glycan trimming. (A) HEK293 cells were 
pretreated with vehicle or 1 µg/ml triacsin C for 16 h, followed by 75 µM emetine for the 
indicated times. Where indicated, 5 µg/ml kifunensine and 5 µM CB-5083 were added at the 
beginning of the emetine chase. SDS lysates were separated on large-format SDS–PAGE gels 
and analyzed by immunoblotting to visualize the different CD147 glycoforms. A darker exposure 
of the CD147(CG) bands is provided to facilitate visualization of the different trimmed 
glycoforms. (B, C) The relative levels of untrimmed CD147(CG) (B) and trimmed CD147(CG) 
(C) were quantified from A and are presented as percentage of the levels at time 0 h (n = 3). 
(D) Lysates from cells treated as in A were incubated with PNGase F as indicated and analyzed 
by immunoblotting. Mat., mature; CG, core glycosylated; -CHO, deglycosylated. Error bars 
indicate SEM.
Volume 28 January 15, 2017 Inhibition of ACSLs impairs ERAD | 275 
and ubiquitin. The significance of Hrd1 association with RPN1 (also 
known as ribophorin I), PGRC1, and EMD is unknown. These proteins 
are not known to be involved in protein quality control and may rep-
resent endogenous substrates of the Hrd1 complex. Several previ-
ously reported Hrd1 complex members (UBXD8, AUP1, derlin-1, 
derlin-2) were not detected in our SILAC experiment, possibly due to 
their lower abundance. Therefore, we examined the association of 
these interactors with Hrd1 by immunoblotting of affinity purified 
S-tagged Hrd1 complexes (Figure 4B). Analysis of the results from 
both the SILAC (Figure 4A) and immunoblotting (Figure 4B) experi-
ments indicate that few Hrd1 interactions were affected by triacsin C 
treatment. The core Hrd1 complex, characterized by SEL1L, FAM8A1, 
XTP3-B, OS-9, and ERLIN2, remained intact after triacsin C treatment. 
There were minor trends toward increased associations with VCP and 
ubiquitin, as well as decreased association with Hsp47.
(Bogdanov et al., 2008; Contreras et al., 2011). To determine whether 
ACSL inhibition affects the composition of the Hrd1 dislocation com-
plex, we used a quantitative triple stable isotope labeling with amino 
acids in cell culture (SILAC) strategy to measure the dynamics of Hrd1 
interactions in response to triacsin C treatment (Figure 4A and Sup-
plemental Tables S1 and S2). The results from this experiment are 
displayed in a two-dimensional plot (Figure 4A), which groups non-
specific background, as well as constitutive and dynamic interactors. 
Of the 145 proteins detected, 15 passed our criteria for high-confi-
dence interactors (SILAC ratio M:L > 2-fold). In addition to the iden-
tification of Hrd1 itself (the bait), the strongest interactors (SILAC 
ratio M:L > 20-fold) were known members of the Hrd1 complex—
SEL1L, FAM8A1, ERLIN2, OS-9, and XTP3-B. Other noteworthy 
interactors that were captured included proteins involved in protein 
folding and degradation, such as VCP, PDI, GRP94, Hsp47, calnexin, 
FIGURE 4: Triacsin C impairs substrate delivery to and dislocation from the Hrd1 complex. (A) Two-dimensional plot 
representing the proteomic analysis of Hrd1-S interactors from a triple SILAC experiment. The ratio of Hrd1-S/control 
on the x-axis indicates the strength of the interaction under basal conditions. The ratio of Hrd1-S + triacsin C/Hrd1-S on 
the y-axis indicates the change in the interaction in response to triacsin C treatment. Gray filled circles are nonspecific 
interactors, and blue filled circles are high-confidence interactors. (B) HEK293 cells expressing an empty vector or 
S-tagged Hrd1 were pretreated with vehicle or 1 µg/ml triacsin C for 16 h. Affinity-purified complexes were analyzed by 
immunoblotting with the indicated antibodies. (C) HEK293 cells were pretreated with vehicle or 1 µg/ml triacsin C for 
16 h. Endogenous Hrd1 complexes were immunoprecipitated and analyzed by immunoblotting with the indicated 
antibodies. (D) The fold change in Hrd1-associated CD147(CG) in C was quantified and is presented as a bar graph 
(n = 3). (E) The split-Venus dislocation assay. See text for description. (F) 293T.FluERAD cells, which stably express the 
deglycosylation-dependent Venus dislocation system, were pretreated with 1 µg/ml triacsin C for 16 h, followed by a 
0- or 6-h treatment with 10 µM MG-132. Where indicated, 5 µg/ml kifunensine or 5 µM CB-5083 was added together 
with 10 µM MG-132 for 0 or 6 h. Venus fluorescence levels were quantified by flow cytometry and are represented as 
the fold change relative to the 0 h. Asterisk indicates a significant decrease in the fold change in fluorescence levels 
(p < 0.05). AP, affinity purification; CG, core glycosylated; endo., endogenous; IP, immunoprecipitation; Mat., mature; 
Sprot, S-protein agarose. Error bars indicate SEM.
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Triacsin C impairs the dislocation of a 
luminal glycosylated ERAD substrate
Given the effects of triacsin C on CD147 
glycan trimming (Figure 3) and association 
with Hrd1 (Figure 4, C and D), we predicted 
that triacsin C would affect substrate dislo-
cation. The accumulation of deglycosylated 
CD147 in response to MG-132 treatment 
provides one potential method to assess 
dislocation. However, MG-132 also stabi-
lized CD147(CG), and the appearance of 
deglycosylated CD147 was minimal and 
difficult to detect (Figure 2C). Therefore, to 
assess quantitatively the effects of triacsin 
C on dislocation, we used a more sensitive 
and robust fluorescent ERAD dislocation 
assay based on the reconstitution of split 
Venus (Figure 4E; Grotzke et al., 2013). In 
this assay, the N-terminal half of deglyco-
sylation-dependent Venus is fused to the 
H2-Kb signal sequence (SS-dgdV1Z), tar-
geting it to the ER lumen (Grotzke et al., 
2013). SS-dgdV1Z is glycosylated, recog-
nized as an aberrant protein, and dislo-
cated into the cytosol for degradation 
(Grotzke et al., 2013). In the presence of 
MG-132, SS-dgdV1Z accumulates in the 
cytosol and associates with the C-terminal 
half of Venus (VZ2), reconstituting the ma-
ture fluorescent protein and enabling dislo-
cation to be measured by flow cytometry 
(Grotzke et al., 2013). Of importance, the 
fluorescence is deglycosylation dependent 
(Grotzke et al., 2013), ensuring that any 
fluorescence detected results from the dis-
location of dgdV1Z from the ER lumen into 
the cytosol.
Incubation of 293T.FluERAD cells stably 
expressing SS-dgdV1Z and VZ2 with MG-
132 resulted in a large increase in Venus 
fluorescence (Figure 4F, 16.4-fold increase). 
In agreement with a role for VCP in SS-dg-
dV1Z dislocation (Grotzke et al., 2013), co-
incubation with CB-5083 and MG-132 
nearly completely blocked the increase in 
fluorescence (Figure 4F, 1.6-fold increase). 
Similar to the effect of kifunensine treat-
ment (Figure 4F, 7.6-fold), triacsin C treat-
ment partially blocked the increase in 
fluorescence in response to MG-132 
(Figure 4F, 7.3-fold). Thus, triacsin C signifi-
cantly reduces the dislocation of a luminal glycosylated ERAD 
substrate.
Lipid droplets are dispensable for CD147 ERAD
The observation that triacsin C inhibits ERAD (Hartman et al., 
2010; Klemm et al., 2011; Jo et al., 2013; Figure 1) is in agreement 
with a role for LDs in ERAD; however, triacsin C is not a selective 
inhibitor of LD biogenesis (Figure 5A). Although a selective inhibi-
tor of LD biogenesis has not been identified, ablation of the diac-
ylglycerol acyltransferase (DGAT) enzymes (DGAT1 and DGAT2), 
which catalyze the final and committed step in TAG synthesis 
To examine a potential effect of triacsin C on the delivery of 
CD147 to the Hrd1 complex, we analyzed endogenous Hrd1 
complexes immunoprecipitated from vehicle- and triacsin C–treated 
cells. Hrd1 bound only the ER-localized core glycosylated form of 
CD147 (Figure 4, C and D), supporting the specificity of the interac-
tion with CD147. Of interest, triacsin C treatment caused a pro-
nounced decrease in the amount of CD147(CG) that coprecipitated 
with Hrd1 (Figure 4, C and D). Thus, our results indicate that whereas 
the overall composition of the Hrd1 dislocation complex is mostly 
unaffected, triacsin C treatment reduces the delivery of the sub-
strate CD147 to the Hrd1 complex.
FIGURE 5: Lipid droplet biogenesis is dispensable for CD147 ERAD. (A) The Kennedy pathway 
of TAG synthesis indicating the enzymes (blue boxes) and metabolites. Select additional 
pathways that use acyl-CoA are also depicted. Approaches to disrupt LD biogenesis through the 
inhibition of ACSLs (triacsin C) or the DGAT enzymes (DGAT1i and DGAT2-/-) are indicated in 
red. (B) DGAT2-/- MEFs were pretreated with 1 µg/ml triacsin C or 20 µM DGAT1i for 3 h and 
then incubated with 200 µM oleate for 0 or 6 h as indicated. Fluorescence microscopy was 
employed to visualize LDs (green) and nuclei (blue). Scale bar, 5 µm. (C) The abundance of LDs 
was quantified from cells treated as shown in B. Asterisk indicates a significant increase in LD 
amount relative to untreated cells (p < 0.05). (D) DGAT2-/- MEFs were pretreated with vehicle, 
1 µg/ml triacsin C, or 20 µM DGAT1i for 16 h, followed by 75 µM emetine for the indicated 
times. CD147 levels were assessed by immunoblotting of SDS lysates. (E) The relative levels of 
CD147(CG) in D were quantified and are presented as percentage of the levels at time 0 h 
(n = 3). ACSL, long-chain acyl-CoA synthetase; AGPAT, acylglycerolphosphate acyltransferase; 
DAG, diacylglycerol; DGAT, diacylglycerol acyltransferase; GPAT, glycerol-phosphate 
acyltransferase; LPA, lysophosphatidic acid; PA, phosphatidic acid; PAP, phosphatidic acid 
phosphatase; TAG, triacylglycerol. Error bars indicate SEM.
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DGAT2-/- MEFs exhibited a low amount of 
LDs under basal conditions, which in-
creased dramatically after a 6-h treatment 
with 200 µM oleate (Figure 5, B and C), in-
dicating that DGAT2-/- MEFs are still able 
to generate LDs in response to an oleate 
challenge, due to the presence of DGAT1. 
Treatment with either triacsin C or DGAT1i 
reduced the amount of LDs in non–oleate-
treated cells and completely blocked the 
increase in LD biogenesis in response to 
oleate (Figure 5, B and C). The levels of the 
LD protein perilipin-2 (PLIN2) are known to 
correlate with LD abundance, and, in the 
absence of LDs, PLIN2 is degraded by the 
ubiquitin-proteasome system (Xu et al., 
2005; Masuda et al., 2006; Takahashi et al., 
2016). Analysis of PLIN2 levels and cellular 
distribution indicate that triacsin C and 
DGAT1i treatments block oleate-induced 
increases in PLIN2 levels and PLIN2-immu-
noreactive LDs (Supplemental Figure S4). 
Together these data demonstrate that the 
DGAT2-/- MEFs provide a facile means to 
acutely manipulate LD biogenesis at an up-
stream step (i.e., with triacsin C) or a down-
stream step (i.e., with DGAT1 inhibitor).
As observed in HEK293 cells, CD147(CG) 
was degraded in DGAT2-/- MEFs during an 
emetine translation shutoff experiment and 
was stabilized by a triacsin C pretreatment 
(Figure 5, D and E). The rate of CD147(CG) 
degradation was greater in the DGAT2-/- 
MEFs than in the HEK293 cells (half-life 
∼25 min vs. ∼2 h). DGAT1i pretreatment, de-
spite inhibiting LD biogenesis (Figure 5, B 
and C), had no effect on the kinetics of 
CD147 degradation (Figure 5, D and E). 
These results argue against a requirement 
for LDs in CD147 degradation and suggest 
that triacsin C affects ERAD through a mech-
anism independent of LDs.
Metabolomic profiling reveals global 
alterations in the cellular lipid 
landscape of triacsin C–treated cells
To understand the effects of triacsin C on cel-
lular lipid homeostasis, we performed tar-
geted single reaction monitoring (SRM)–
based liquid chromatography–tandem mass 
spectrometry (LC-MS/MS) steady-state lipi-
domic profiling of >100 lipid metabolites, 
encompassing a wide array of lipid classes, 
including neutral lipids, fatty acids, acyl carni-
tines (ACs), N-acyl ethanolamines, sterols, 
phospholipids, sphingolipids, lysophospho-
lipids, and ether lipids (Figure 6 and Supplemental Table S3). Among 
the 118 lipids, 71 exhibited significant changes (p < 0.05) after a 16-h 
triacsin C treatment (Figure 6, A–K). As expected, we observed a 
prominent decrease in the levels of many neutral lipids—monoacylg-
lycerols (MAGs), diacylglycerols (DAGs), and TAGs (Figure 6, B and C). 
Not all species of TAG were reduced (e.g., C16:0/C20:4/C16:0 TAG 
(Figure 5A), causes a complete blockade of LD biogenesis in adi-
pocytes (Harris et al., 2011). Therefore, to examine a role for LDs in 
ERAD, we exploited a recently developed DGAT1 inhibitor, T863 
(DGAT1i) (Cao et al., 2011), and mouse embryonic fibroblast (MEF) 
cell lines lacking DGAT2 (DGAT2-/-; Stone et al., 2004; Harris 
et al., 2011) to simultaneously disrupt both DGAT enzymes. The 
FIGURE 6: Triacsin C alters the cellular lipid landscape. Targeted metabolomic analysis of the 
nonpolar metabolome of cells treated with 1 µg/ml triacsin C for 16 h revealed alterations in 71 
lipid species, illustrated as a volcano plot (A) and a heat map organized by lipid class (B). Red text 
in B indicates a significant change (p < 0.05). (C–K) Quantification showing the relative levels of 
significantly altered lipids (n = 4 or 5). *p < 0.05, **p < 0.01. White bars, vehicle; black bars, triacsin 
C. (L) Pathway map depicting the general effects of triacsin C on neutral lipids and phospholipids. 
DAG, diacylglycerol; FFA, free fatty acid; MAG, monoacylglycerol; NAE, N-acylethanolamine; PA, 
phosphatidic acid; PC, phosphatidylcholine; PE phosphatidy lethanolamine; PG, phosphatidy-
lglycerol; PI, phosphatidylinositol; PS, phosphatidylserine; TAG, triacylglycerol. “L” before a lipid 
phospholipid designation indicates lyso-; “e” after a lipid designation indicates an ether lipid; “p” 
after a lipid designation designates plasmalogen. Error bars indicate SEM.
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C/EBP homologous protein (CHOP; Hiramatsu et al., 2015). To ex-
amine the potential effect of triacsin C on PERK induction of stress-
responsive genes, we exploited a clonal HEK293 reporter cell 
line expressing an 8.5-kb CHOP gene fragment fused to GFP 
(CHOP::GFP; Wang et al., 1998; Novoa et al., 2001). Treatment with 
tunicamycin, an inhibitor of N-linked glycosylation that induces the 
UPR, resulted in a robust and rapid accumulation in GFP fluorescence 
(Figure 7C and Supplemental Figure S5). Treatment with triacsin C 
also caused an increase in GFP fluorescence but with different tem-
poral dynamics. During the first 8 h, no increase in GFP fluorescence 
was observed (Figure 7C). This lag period was followed by an in-
crease in GFP fluorescence levels at 16 and 24 h (Figure 7C).
The IRE1 and PERK arms of the UPR play well-characterized pro-
tective roles through the induction of genes involved in protein fold-
ing and membrane expansion and through the repression of transla-
tion (Walter and Ron, 2011). Of note, UPR up-regulation protected 
yeast from ER trafficking and ERAD defects induced by lipid disequi-
librium (Thibault et al., 2012). However, persistent activation of IRE1 
or PERK can lead to cell death (Lin et al., 2007; Han et al., 2009). To 
determine the role of the IRE1 and PERK pathways in the cellular 
response to triacsin C treatment, we analyzed the effects of the IRE1 
inhibitor 4µ8c (IRE1i) and PERK inhibitor GSK2606414 (PERKi). IRE1i 
completely blocked triacsin C–induced XBP1 cleavage (Figure 7, A 
and B), and PERKi significantly attenuated the induction of the 
CHOP::GFP reporter (Figure 7D). Inhibition of PERK increased the 
amounts of cell death induced by triacsin C at 8, 16, and 24 h (Figure 
7E), indicating that PERK plays a predominantly protective role un-
der these conditions. In contrast, inhibition of IRE1 had little effect 
during triacsin C treatment and increased the amount of cell death 
at 24 h (Figure 7E). These findings indicate that both the IRE1 and 
PERK arms of the UPR are induced by triacsin C, but that the outputs 
of these two signaling pathways have opposing effects on cell 
viability.
DISCUSSION
Although there are several intriguing connections between LDs and 
ERAD, whether LDs are directly involved in the ERAD mechanism 
has remained an outstanding question. Our data argue that LD bio-
genesis is not a fundamental requirement for ERAD. Instead, our 
results support a model (Figure 7F) in which triacsin C inhibition of 
ACSLs causes widespread changes in the cellular lipid composition 
that impair specific steps in ERAD, resulting in disruptions in ER pro-
teostasis, activation of the UPR, and eventual cell death. Thus, dys-
regulated fatty acid metabolism negatively affects ER homeostasis 
and protein quality control independently of LDs.
To inhibit LD biogenesis but avoid the broad effects that ACSL 
inhibition has on lipid homeostasis, we pursued an approach that 
would disrupt a downstream step in TAG synthesis. To this end, we 
characterized a combined chemical (DGAT1 inhibition) and genetic 
(DGAT2-/-) approach to inhibit both of the DGAT enzymes, which are 
required for the conversion of DAG to TAG and the generation of 
LDs (Yen et al., 2008; Harris et al., 2011). This strategy enabled acute 
disruption of LD biogenesis, reducing LD abundance under basal 
and oleate-stimulated conditions as effectively as triacsin C does. In 
contrast to triacsin C, disruption of LD biogenesis by inhibiting the 
DGATs had no effect on the kinetics of CD147 ERAD. These results 
are consistent with previous analyses of ERAD in yeast models of LD 
disruption (Olzmann and Kopito, 2011; Nakatsukasa and Kamura, 
2016), which together demonstrate that LD biogenesis is not integral 
to the ERAD mechanism in yeast or mammalian cells. The possibility 
that LDs may function in the degradation of specific substrates or in 
ERAD under specific conditions is still worth consideration. For 
and C18:0/C18:0/C18:0 TAG; Figure 6, B and C), suggesting that 
there may be protected pools of TAGs or that some ACSLs that are 
incompletely inhibited mediate the formation of these specific TAGs 
(Igal et al., 1997). We also observed an anticipated decrease in AC 
levels, particularly in C16:0 AC (Figure 6, B and E). Although free fatty 
acids might be expected to accumulate due to the inhibition of AC-
SLs and consequent lack of conversion into the CoA intermediate for 
cellular use, no changes in fatty acid levels were detected (Figure 6B). 
This may be due to a compensatory efflux of free fatty acids (Igal 
et al., 1997), which could result in an underestimate of total free fatty 
acid levels, or increased flux through ACSL enzymes that are not 
inhibited.
Broad changes in additional cellular lipids were also observed, 
including decreases in many phospholipids, phospholipid ethers, 
neutral ether lipids, and lysophospholipid ethers (Figure 6, B–K). 
The decreases in lipid levels presumably resulted from impairments 
in synthesis caused by the inability of ACSLs to activate fatty acids, 
a requirement for conjugation. Particularly striking was the general 
decrease in nearly all phosphatidylinositol and phosphatidylinositol 
ether lipids (Figure 6, B, F, and J). This is interesting, given the recent 
finding that phosphatidylinositol maintains ER homeostasis in yeast 
by sequestering fatty acids when LD biogenesis is inhibited 
(Velázquez et al., 2016). Our results suggest that phosphatidylinosi-
tol may represent an especially dynamic phospholipid pool that re-
flects the levels of fatty acid flux.
Several lipid species displayed significant increases, including 
many lysophospholipids (Figure 6, B, D, and H), which can act as 
signaling molecules, and several phospholipids (Figure 6, B–K). The 
increase in some lipids is consistent with the possible increased flux 
of fatty acids through ACSL enzymes that are not inhibited or are 
incompletely inhibited by triacsin C. The ratio of phosphatidylcho-
line (PC) to phosphatidylethanolamine (PE) has been implicated in 
ER homeostasis (Li et al., 2006; Fu et al., 2011; Thibault et al., 2012), 
and although we observed alterations in PC and PE levels (Figure 6, 
B and F), the ratio between the two lipid species was relatively un-
changed. An increase in ceramides (C16:0 ceramide and C18:0 ce-
ramide) was detected (Figure 6, B and G), which is notable, given 
their role in cellular stress responses and UPR activation (Volmer and 
Ron, 2015). Together our results indicate that triacsin C treatment 
not only affects the levels of neutral lipids sequestered in LDs, but it 
also causes widespread alterations in the cellular lipid landscape 
(Figure 6). The levels of several of the altered lipids have been sug-
gested to affect ER homeostasis (e.g., phosphosphatidylinositol and 
ceramides).
Triacsin C activation of the PERK and IRE1 arms of the 
UPR has opposing effects on cell viability
Disruptions in ERAD and in lipid homeostasis can activate the UPR 
(Jonikas et al., 2009; Volmer and Ron, 2015). Inositol-requiring en-
zyme-1 (IRE1), an ER transmembrane serine/threonine kinase and 
endonuclease, is a primary mediator of the UPR that splices XBP1 
mRNA to enable the translation of the XBP1 transcription factor 
(Walter and Ron, 2011). Analysis using reverse transcription PCR re-
vealed that incubation with triacsin C induced XBP1 splicing (Figure 
7A). The spliced form of XBP1 was detectable at low levels as early 
as 8 h, and it became much more prominent at 16 and 24 h (Figure 
7A). A second arm of the UPR is controlled by the ER-resident kinase 
PKR-like ER kinase (PERK), which phosphorylates the α subunit of 
eukaryotic translation-initiation factor 2 (eIF2α). Phosphorylation of 
eIF2α represses global translation while simultaneously promoting 
the translation of the ATF4 transcription factor to up-regulate stress-
responsive genes such as the proapoptotic transcription factor 
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Our findings are in agreement with previ-
ous reports that triacsin C impairs ERAD 
(Hartman et al., 2010; Klemm et al., 2011; Jo 
et al., 2013). Indeed, we found that triacsin C 
inhibited the degradation of two glycosyl-
ated Hrd1 substrates—the luminal substrate 
NHK and the endogenous integral mem-
brane substrate CD147. The highest amount 
of substrate stabilization required a 16-h pre-
treatment with triacsin C, suggesting that 
ACSL activity is not required acutely during 
ERAD but instead that ACSL activity is re-
quired to establish a particular cellular envi-
ronment conducive for ERAD. To define 
more precisely the step in ERAD that is af-
fected by triacsin C, we tested individual 
steps of ERAD in the context of triacsin C 
treatment. Our results indicate that the triac-
sin C–induced defect in protein degradation 
is upstream of the proteasome and is con-
fined to a subset of ERAD pathways. This 
conclusion is supported by several findings: 
1) ubiquitinated proteins did not accumulate 
in response to triacsin C, 2) triacsin C did not 
stabilize a cytosolic UPS substrate, 3) triacsin 
C affected a subset of ERAD substrates—
CD147 and NHK—but not CFTR∆F508, and 
4) triacsin C impaired the dislocation of a lu-
minal glycosylated substrate. Moreover, 
analyses of the glycosylation state of CD147 
during degradation indicate that triacsin C 
treatment impaired CD147 glycan trimming 
and delivery to the Hrd1 complex, suggest-
ing that the primary impairment in ERAD is 
due to the failure to expose the trimmed gly-
can structure necessary for degradation 
commitment. Our proteomics data indicate 
that the composition of the Hrd1 complex is 
largely unaltered in triacsin C–treated cells; 
however, it is possible that alterations in the 
ER lipid composition could modulate the 
structure and/or function of the complex. 
The enzymes involved in the trimming of 
CD147’s glycans are unknown, but this step 
is most likely catalyzed by ER-resident man-
nosidases ERManI and/or EDEM1-3. Disrup-
tions in lipid composition could influence 
substrate localization to ERManI-containing 
ER subdomains (Benyair et al., 2015) or could 
affect EDEM membrane association, which is 
known to affect EDEM glycan trimming activ-
ity toward certain substrates (Tamura et al., 
2011). It is also possible that the inhibition of 
ACSLs could influence protein acylation, and 
both calnexin (Lakkaraju et al., 2012; Lynes et al., 2012, 2013) and the 
ERAD E3 ligase gp78 (Fairbank et al., 2012) have been reported to 
be palmitoylated. Whether other ERAD factors are regulated by lipid 
modifications is unknown.
Activation of the UPR initiates signaling pathways with opposing 
outputs, a protective response that seeks to reestablish ER homeo-
stasis and an apoptotic response that promotes cell death in the 
face of persistent ER stress (Lin et al., 2007, 2009; Hetz, 2012; 
example, for ApoB100, an extremely large, hydrophobic protein, the 
association with LDs might provide a specialized ERAD mechanism 
to reduce aggregation (Ohsaki et al., 2006; Suzuki et al., 2012). LDs 
may also contribute to ERAD only under particular conditions, such 
as periods of disrupted proteostasis. Under conditions in which pro-
teasomal capacity is limiting, the LD surface could act as a transient 
site for the sequestration of ERAD and other UPS substrates (Ohsaki 
et al., 2006; Vevea et al., 2015).
FIGURE 7: Triacsin C activates opposing arms of the UPR. (A) Reverse transcription PCR assay 
of XBP1 mRNA from HEK293 cells treated with 1 µg/ml triacsin C for the indicated times in the 
presence and absence of 100 µM IRE1 inhibitor 4µ8c (IRE1i). XBP1 amplicons were separated on 
an agarose gel and imaged. XBP1u, unspliced XBP1; XBP1s, spliced XBP1. (B) Quantification of 
the percentage of spliced XBP1 in A (n = 3). (C) HEK293 cells stably expressing a CHOP::GFP 
construct were treated with vehicle, 1 µg/ml triacsin C, or 5 µg/ml tunicamycin as indicated and 
GFP levels measured using flow cytometry. The fold change in GFP fluorescence relative to time 
0 h is shown (n = 3). (D) HEK293 cells stably expressing a CHOP::GFP construct were treated 
with vehicle or 1 µg/ml triacsin C for 0 and 16 h in the presence and absence of 1 µM PERK 
inhibitor GSK2606414 (PERKi). GFP levels were measured using flow cytometry. The fold change 
in GFP fluorescence relative to time 0 h is shown (n = 3). (E) HEK293 cells were treated with 
1 µg/ml triacsin C and vehicle, 100 µM IRE1i, or 1 µM PERKi for the indicated times and stained 
with propidium iodide to identify apoptotic cells. The percentage of apoptotic cells relative to 
time 0 h is shown (n = 3). (F) A model depicting the relationship between fatty acid metabolism 
and ER proteostasis. Disruptions in fatty acid metabolism result in lipid disequilibrium, causing 
impairments in ER quality control by inhibiting specific steps in ERAD (independent of LDs). The 
disruption in ER homeostasis activates the UPR, which protects cells via the PERK pathway and 
eventually kills cells via the IRE1 pathway. Error bars indicate SEM.
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gram), anti–ubiquitin conjugates (FK2; EMD Millipore), anti-AUP1 
(Proteintech), anti-SEL1L (T-17; Santa Cruz Biotechnology) and anti-
KDEL (Enzo). Anti–derlin-1 and anti–derlin-2 antibodies were kind 
gifts from Yihong Ye (National Institutes of Health, Bethesda, MD). 
Rabbit polyclonal anti-UBXD8 antibodies were generated against a 
histidine-tagged fragment of UBXD8 (amino acids 97–445) by Pro-
teintech Group. All IRDye680- and IRDye800-conjugated secondary 
antibodies for Western blotting were obtained from LI-COR. Alexa 
Fluor–conjugated secondary antibodies for immunofluorescence mi-
croscopy were obtained from Thermo Fisher Scientific.
Reagents employed in this study include triacsin C (Enzo Life Sci-
ences), emetine dihydrochloride hydrate (Sigma-Aldrich), CB-5083 
(Anderson et al., 2015; Cleave Biosciences), oleate (Sigma-Aldrich), 
kifunensine (Cayman Chemical), deoxynojirimycin (Sigma-Aldrich), 
MG-132 (Selleck Chemicals), T863 (Sigma-Aldrich), 4µ8C (EMD 
Millipore), GSK2606414 (EMD Millipore), tunicamycin (Cayman 
Chemical), and PNGase F (New England Biolabs).
Cell culture and transfections
HEK293, HEK293T, MEF, HeLa, and U2OS cells were cultured in 
DMEM containing 4.5 g/l glucose and l-glutamine (Corning) sup-
plemented with 10% fetal bovine serum (FBS) (Thermo Fisher Scien-
tific and Gemini Bio Products) at 37°C and 5% CO2. 293T.FluERAD 
cells stably expressing a split-Venus system for the analysis of the 
dislocation step of ERAD (Grotzke et al., 2013) were kindly provided 
by Peter Cresswell (Yale University, New Haven, CT). U2OS cells sta-
bly expressing Venus-DD (Bersuker et al., 2016) and HEK293 cells 
stably expressing the CHOP::GFP reporter were kindly provided by 
Ron Kopito (Stanford University, Stanford, CA). DGAT2-/- MEF cells 
were kindly provided by Robert Farese, Jr. (Harvard University, 
Cambridge, MA). All plasmid transfections were performed using 
X-tremeGENE HP (Roche) transfection reagent according to the 
manufacturer’s instructions.
Immunoblotting analysis
Cells were washed extensively in phosphate-buffered saline (PBS) 
and lysed in 1% SDS. Protein amounts were normalized using a 
bicinchoninic acid (BCA) protein assay (Thermo Fisher Scientific). 
Proteins were separated on 4–20% polyacrylamide gradient gels 
(Bio-Rad) and transferred onto low-fluorescence polyvinylidene fluo-
ride or nitrocellulose membranes (Bio-Rad). Large-format gel elec-
trophoresis was performed using 10% acrylamide gels made with 
acrylamide/bis 19:1. Membranes were incubated in 5% nonfat milk 
in PBS plus 0.1% Tween-20 (PBST) for 30 min to reduce nonspecific 
antibody binding. Membranes were then incubated for at least 2 h 
in PBST containing 5% milk or 1% bovine serum albumin (BSA; 
Sigma-Aldrich) and primary antibodies, followed by incubation for 
at least 1 h in PBST containing 1% BSA and fluorescence-conjugated 
secondary antibodies. Immunoblots were visualized on a LI-COR 
imager (LI-COR Biosciences), and ImageJ (Schneider et al., 2012) 
was used for quantification.
Immunofluorescence microscopy
HeLa and MEF cells were plated on poly-l-lysine–coated cover-
slips. Cells were treated the next day, washed with PBS, and fixed 
at room temperature with 4% paraformaldehyde in PBS for 10 min. 
Cells were washed three times with PBS and permeabilized with 
0.1% Triton X-100 plus 1% BSA in PBS at room temperature for 
30 min. Cells were washed three times with 1% BSA in PBS 
and incubated for 2 h in primary antibodies, washed three times, 
and incubated for 1 h with Alexa Fluor–conjugated secondary an-
tibodies, BODIPY493/503 (LD staining; Thermo Fisher Scientific), 
Lu et al., 2014). Consistent with disruptions in ER homeostasis, 
treatment with triacsin C induced XBP1 splicing (IRE1 arm) and 
CHOP::GFP expression (PERK arm) and eventually caused cell 
death. Treatment of cells with the UPR inducer tunicamycin causes 
a rapid and transient up-regulation of IRE1 signaling that is paral-
leled by a slower increase in apoptotic PERK signaling at later times 
(Lin et al., 2007). Of interest, in response to triacsin C, we see very 
different temporal dynamics and effects of UPR induction. Both the 
PERK and IRE1 arms exhibited similar activation kinetics and, after 
an initial lag period, steadily increased until the end of our experi-
ments. Despite increasing CHOP reporter expression, PERK actions 
were overall protective in response to triacsin C. This finding indi-
cates that CHOP expression alone is not conclusive evidence of a 
proapoptotic signaling output, consistent with the observation that 
forced CHOP expression was insufficient to induce cell death (Han 
et al., 2013). In contrast to PERK, IRE1 signaling appeared to pro-
mote cell death, and the inhibition of IRE1 attenuated triacsin C–
induced apoptosis, possibly by inhibiting excessive regulated 
Ire1-dependent decay (RIDD) of important secretory transcripts 
(Han et al., 2009) or activation of a JNK apoptotic signaling pathway 
(Urano et al., 2000). These results highlight the complex relationship 
between the UPR and cell death and reveal that the mode of UPR 
activation (e.g., tunicamycin vs. triacsin C) has a profound effect on 
the ultimate effects of each UPR branch. Alterations in phospholip-
ids can directly induce UPR signaling (Volmer et al., 2013; Volmer 
and Ron, 2015), and whether the changes in the lipid environment, 
the defects in ER protein quality control, or both are responsible for 
triacsin C activation of the UPR is unclear. In addition, how the UPR 
is customized to fit a particular ER stressor is not evident. It is pos-
sible that the temporal coordination of individual UPR branches in-
fluences the end output (i.e., protection vs. cell death) or that differ-
ent ER stressors provide a unique “second hit” (e.g., disruptions in 
lipid homeostasis or depletion in ER calcium pools) that sensitizes 
cells to IRE1- or PERK-dependent cell death pathways.
Our study reveals an intimate relationship between cellular lipid 
homeostasis and ER protein quality control. Our findings raise the 
possibility that certain lipid environments and/or modifications may 
affect ER proteostasis by regulating specific steps of the ERAD pro-
cess. It is worth noting that a multitude of diseases, ranging from 
obesity to neurodegenerative diseases, are associated with altered 
lipid homeostasis and upregulated UPR (Hetz et al., 2013). In addi-
tion, targeting lipid metabolic enzymes to decrease fatty acid avail-
ability (e.g., inhibition of FASN) is being actively pursued as a thera-
peutic strategy for the treatment of cancer (Menendez and Lupu, 
2007; Currie et al., 2013; Benjamin et al., 2015). Therefore, elucidat-
ing the connections between ER lipid and protein homeostasis 
could have significant ramifications for our understanding of the 
pathogenic mechanisms underlying a wide number of diseases.
MATERIALS AND METHODS
Plasmids, antibodies, and reagents
The pcDNA3.1(-) plasmids for expression of TTR-HA, the null Hong 
Kong mutant of α-1 antitrypsin (NHK-HA and NHK-GFP), and S-
tagged Hrd1 (Hrd1-S) were previously described (Christianson et al., 
2008, 2012). The CFTR∆F508 plasmid was kindly provided by Doug 
Cyr (University of North Carolina at Chapel Hill, Chapel Hill, NC).
Antibodies employed in this study include anti-CD147 (A-12, 
G-19, 8D6; Santa Cruz Biotechnology), anti-Hrd1 (A302-946A; 
Bethyl), anti-HA (HA7; Sigma-Aldrich), anti–S-peptide (EMD Milli-
pore), anti-tubulin (Abcam), anti–glyceraldehyde-3-phosphate dehy-
drogenase (EMD Millipore), anti-GFP (Roche), anti-CFTR (University 
of North Carolina at Chapel Hill, CFTR Antibodies Distribution Pro-
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beled. At 16 h before harvest, the S-tagged Hrd1 cells were incu-
bated with either vehicle (medium SILAC labeled) or 1 µg/ml triacsin 
C (heavy SILAC labeled). After several washes in PBS, cells were 
lysed in IP buffer, and 3 mg of protein lysate was loaded onto 75 µl 
of S-protein agarose beads (EMD Millipore). Lysates were rotated at 
4°C for 2 h and washed three times with IP buffer containing 0.1% 
digitonin and twice with 50 mM ammonium bicarbonate. Beads 
were resuspended in 75 µl of 0.2% RapiGest SF (Waters) in 50 mM 
ammonium bicarbonate for 15 min at 65°C, followed by incubation 
with 2.5 µg of trypsin (Thermo Fisher Scientific) overnight at 37°C. 
The affinity purification for each condition was performed separately 
to prevent exchange of interaction partners during the incubations. 
After the proteolysis step, equal volumes of digested peptides were 
combined and acidified with HCl to pH 2.0. Rapigest SF precipitate 
was removed by centrifugation at 20,000 × g for 30 min and the 
peptide solution concentrated to 40 µl using a SpeedVac. Digested 
peptides were analyzed by LC-MS/MS on a Thermo Scientific Q Ex-
active Orbitrap Mass spectrometer in conjunction with a Proxeon 
Easy-nLC II HPLC (Thermo Fisher Scientific) and Proxeon nanospray 
source at the University of California, Davis, Proteomics Core Facility. 
The digested peptides were loaded onto a 100 µm × 25 mm Magic 
C18 100-Å 5U reverse-phase trap, where they were desalted online 
before being separated using a 75 µm × 150 mm Magic C18 200-Å 
3U reverse-phase column. Peptides were eluted using a 180-min 
gradient with a flow rate of 300 nl/min. An MS survey scan was ob-
tained for the m/z range 300–1600, and MS/MS spectra were ac-
quired using a top 15 method, in which the top 15 ions in the MS 
spectra were subjected to high-energy collisional dissociation. An 
isolation mass window of 1.6 m/z was used for the precursor ion 
selection, and a normalized collision energy of 27% was used for 
fragmentation. A 5-s duration was used for the dynamic exclusion. 
The acquired MS/MS spectra were searched against a full UniProt 
database of human protein sequences, and SILAC ratios were deter-
mined using MaxQuant. The mass spectrometry proteomics data 
have been deposited to the ProteomeXchange Consortium via the 
PRIDE partner repository with the data set identifier PXD005633.
Lipidomic profiling
HEK293 cells were grown to 70% confluence in a 10-cm dish and 
treated for 16 h with vehicle or 1 µg/ml triacsin C. Cells were washed 
twice with PBS and harvested, and cell pellets were stored at −80°C. 
Lipid metabolite extraction and analysis by SRM-based LC-MS/MS 
was performed as previously described (Benjamin et al., 2013, 2015; 
Mulvihill et al., 2014). Briefly, nonpolar lipid metabolites were ex-
tracted in 2:1:1 chloroform/methanol/PBS supplemented with inter-
nal standards C12:0 dodecylglycerol (10 nmol) and pentadecanoic 
acid (10 nmol). The organic and aqueous layers were collected after 
separation by centrifugation at 1000 × g for 5 min. The aqueous 
layer was acidified by addition of 0.1% formic acid and subjected to 
a second chloroform extraction. The resulting organic layers were 
combined and mixed, dried down under N2, and dissolved in 120 µl 
of chloroform. A 10-µl aliquot was analyzed by SRM LC-MS/MS. 
Metabolites were separated using a Luna reverse-phase C5 column 
(Phenomenex), and MS analysis was performed on an Agilent 6430 
QQQ LC-MS/MS. Quantification of metabolites was performed by 
integrating the area under the peak, normalized to internal standard 
values, adjusted based on external standard curves, and expressed 
as relative levels compared with the control sample.
XBP1 splicing assay
RNA was isolated using TRIzol Reagent (Life Technologies) and cDNA 
generated using the High-Capacity cDNA Reverse Transcription Kit 
and 4′,6-diamidino-2-phenylindole (DAPI; nuclei staining; Thermo 
Fisher Scientific). Cells were washed three times and mounted us-
ing Fluoromount-G (SouthernBiotech). Cells were visualized using 
a DeltaVision Elite microscope and acquired images deconvolved 
and analyzed using SoftWoRx. The abundance of LDs per cell was 
determined by measuring the area of BODIPY493/503–stained 
LDs per cell using ImageJ (Schneider et al., 2012).
Affinity purifications
HEK293 cells were harvested, washed with PBS, and lysed in immu-
noprecipitation (IP) buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 
1% digitonin, and protease inhibitor tablets [Thermo Fisher Scien-
tific]) at 4°C for 30 min. Lysates were clarified by centrifugation at 
20,000 × g for 10 min. Protein concentrations were measured using 
the BCA assay. For the affinity purification of S-tagged protein com-
plexes, lysates were loaded onto S-protein agarose beads (EMD 
Millipore) at a concentration of 25 µl beads per 1 mg of lysate. For 
endogenous Hrd1 IPs, 2 mg of lysate was incubated with anti-Hrd1 
antibodies for 1 h and then loaded onto 25 µl of protein G agarose 
beads (EMD Millipore). Lysates were incubated with the beads rotat-
ing at 4°C for 2 h, washed three times with lysis buffer containing 
0.1% digitonin, and eluted in loading buffer.
Radiolabeling and pulse-chase analysis
HEK293 cells plated on poly-l-lysine–coated plates were washed 
twice with “cold” medium, which lacked l-methionine and l-cyste-
ine and contained 10% dialyzed FBS, and then starved in this 
medium for 30 min. Cells were radiolabeled in medium containing 
125 µCi/ml 35S-labeled cysteine/methionine (Easytag Express Pro-
tein Labeling Mix 35S; PerkinElmer) for 30 min, washed twice with 
Hanks’ buffered saline solution, and then chased in complete me-
dium containing 75 µM emetine for the indicated times. Cells were 
harvested, collected by centrifugation, washed in PBS, and lysed in 
pulse-chase IP buffer (25 mmol/l 4-(2-hydroxyethyl)-1-pipera-
zineethanesulfonic acid buffer, pH 7.4, 150 mmol/l NaCl, 5 mmol/l 
MgCl2, 1% 3-[(3-cholamidopropyl)dimethylammonio]-1-propane-
sulfonate detergent, and protease inhibitors). Lysates were cleared 
by centrifugation at 20,000 × g for 15 min at 4°C and protein con-
centrations determined using the BCA assay. Lysates were pre-
cleared with protein G beads (EMD Millipore). CD147 was immuno-
precipitated from lysates by incubation with anti-CD147 antibody 
(8D6; Santa Cruz biotechnology) for 4 h at 4°C with mixing, fol-
lowed by incubation with protein G beads (EMD Millipore) for an 
additional 2 h at 4°C with mixing. Immunoprecipitated proteins 
were washed thrice with the pulse-chase IP buffer and then sepa-
rated by SDS–PAGE. Gels were dried and exposed to a Storage 
Phosphor Screen (GE Healthcare Life Sciences) for 16 h at room 
temperature. Radioactive signals corresponding to CD147(Mat.) 
and CD147(CG) were detected using a Typhoon 9400 Molecular 
Imager (GE Healthcare Life Sciences).
SILAC mass spectrometry
Parental HEK293 cells or HEK293 cells expressing S-tagged Hrd1 
were grown in DMEM lacking l-arginine and l-lysine supplemented 
with 10% dialyzed FBS (Life Technologies) and the appropriate SI-
LAC amino acids: light, l-arginine (Arg0) and l-lysine (Lys0); medium, 
13C6-l-arginine (Arg6) and 4,4,5,5-D4-l-lysine (Lys4); and heavy, 
13C615N4-l-arginine (Arg10) and 13C615N2-l-lysine (Lys8). Cells were 
cultured for at least seven cell doublings to allow for complete incor-
poration of the stable isotope-labeled amino acids (Cambridge Iso-
tope Laboratories). Parental HEK293 control cells were light SILAC 
labeled, and S-tagged Hrd1 cells were either medium or heavy la-
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